You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Therapeutic Index study: Watch Dr David Leather, GSK, talk about therapeutic index of three ICS molecules

Video player requires JavaScript enabled. You can download this video here:

Relvar Ellipta was superior to other ICS/LABAs in helping 25% more patients improve asthma control in everyday clinical practice1

  • With Relvar Ellipta, significantly more patients saw an improvement in ACT score ≥3 or a total score ≥20 (70% vs 56%)*1

See data from Relvar Ellipta's effectiveness RCT

Could Relvar Ellipta help your patients in their everyday lives?

Relvar Ellipta shows greater improvements across all 5 ACT components vs. other ICS/LABAs**2

See more patient data comparing Relvar Ellipta to other ICS/LABAs.

Relvar Ellipta - superior vs. other ICS/LABAs in helping more patients in everyday clinical practice improve their quality of life2

  • With Relvar Ellipta, significantly more patients saw an improvement in AQLQ score at 12 months, with an increase from baseline of ≥0.5 units (56% vs 44%) — (1.79, 95% CI 1.51-2.13, p<0.001) 27% more patients had an improved quality of life vs. ICS/LABAs††1

Relvar Ellipta was superior across all domains of the AQLQ vs. other ICS/LABAs2

See how Relvar Ellipta can improve patients’ QoL vs. other ICS/LABAs

See how Relvar Ellipta is designed for effectiveness


*The primary endpoint was the proportion of ACT responders (improvement from baseline of >=3 or achieving a total ACT of >=20) in patients initiating Relvar vs. continuing usual care (as prescribed by GP) at months 6 in the PEA (primary effectiveness analysis) population. The primary endpoint was met (p<0.001). Data presented are from a subset of patients in the PEA population prescribed ICS/LABA at 
baseline: 70% of patients initiating with Relvar (n=637/908) improved asthma control vs. 56% of patients continuing on their ICS/LABA (n=511/916). OR 1.95, 95% CI: 1.60, 2.38.

In this study there was no difference in serious adverse events reported between Relvar Ellipa and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia. 25% relative difference in responders;14% absolute difference.

** Statistical analysis was not performed on the individual questions of the ACT.

Quality of life was measured by the Asthma Quality of Life Questionnaire at 12 months, a clinically meaningful improvement is defined as an increase from baseline of ≥0.5 units.1 Data presented are from a subset of patients in the ITT population prescribed ICS/LABA at baseline who were initiated with Relvar Ellipta or continued on their existing ICS/LABA: 27% relative difference in responders; 12% absolute difference.

†† (27% vs 12% absolute reduction).

Analysis of the environmental stimuli domain was pre-planned.

§Data presented from a post-hoc analysis.


  1. Woodcock A et al. Lancet 2017; 390:2247–2255.
  2. Svedsater H et al. Respir Med 2018; 141:198–206.
  3. Relvar Ellipta SmPC, available on January 2020.

RELVAR Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.